-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $37

Benzinga·08/05/2026 15:21:21
Listen to the news
RBC Capital analyst Brian Abrahams maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and raises the price target from $36 to $37.